A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
An open label, dose-escalation study to evaluate safety, tolerability, maximum tolerated dose
(MTD), efficacy, and pharmacokinetics (PKs) of CPI-613 given twice weekly for three
consecutive weeks in cancer patients
The objectives of this study are:
- To determine the safety and MTD of CPI-613 when administered 2x weekly for 3 consecutive
weeks.
- To determine pharmacokinetics of CPI-613 following intravenous (IV) administration.
- To observe the anti-tumor effects of CPI-613, if any occur.
Phase:
Phase 1
Details
Lead Sponsor:
Cornerstone Pharmaceuticals, Inc. Rafael Pharmaceuticals Inc.